|
1
|
Ohhara Y, Fukuda N, Takeuchi S, Honma R,
Shimizu Y, Kinoshita I and Dosaka-Akita H: Role of targeted therapy
in metastatic colorectal cancer. World J Gastrointest Oncol.
8:642–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
ELHadi A, Ashford-Wilson S, Brown S, Pal
A, Lal R and Aryal K: Effect of social deprivation on the stage and
mode of presentation of colorectal cancer. Ann Coloproctol.
32:128–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miyo M, Konno M, Nishida N, Sueda T,
Noguchi K, Matsui H, Colvin H, Kawamoto K, Koseki J, Haraguchi N,
et al: Metabolic adaptation to nutritional stress in human
colorectal cancer. Sci Rep. 6:384152016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu K, Shen K, Liang X, Li Y, Nagao N, Li
J, Liu J and Yin P: MiR-139-5p reverses
CD44+/CD133+-associated multidrug resistance
by downregulating NOTCH1 in colorectal carcinoma cells. Oncotarget.
7:75118–75129. 2016.PubMed/NCBI
|
|
6
|
Kim HA, Koo BK, Cho JH, Kim YY, Seong J,
Chang HJ, Oh YM, Stange DE, Park JG, Hwang D, et al: Notch1
counteracts WNT/β-catenin signaling through chromatin modification
in colorectal cancer. J Clin Invest. 122:3248–3259. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bu P, Chen KY, Chen JH, Wang L, Walters J,
Shin YJ, Goerger JP, Sun J, Witherspoon M, Rakhilin N, et al: A
microRNA miR-34a-regulated bimodal switch targets Notch in colon
cancer stem cells. Cell Stem Cell. 12:602–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furukawa S, Kawasaki Y, Miyamoto M,
Hiyoshi M, Kitayama J and Akiyama T: The miR-1-NOTCH3-Asef pathway
is important for colorectal tumor cell migration. PLoS One.
8:e806092013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen F, Liu X, Bai J, Pei D and Zheng J:
The emerging role of RUNX3 in cancer metastasis (Review). Oncol
Rep. 35:1227–1236. 2016.
|
|
10
|
Llorca-Cardeñosa MJ, Fleitas T,
Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini
C, Navarro L, Gambardella V, Castillo J, Roselló S, et al:
Epigenetic changes in localized gastric cancer: The role of RUNX3
in tumor progression and the immune microenvironment. Oncotarget.
7:63424–63436. 2016.PubMed/NCBI
|
|
11
|
Song XY, Li BY, Zhou EX and Wu FX: The
clinicopathological significance of RUNX3 hypermethylation and mRNA
expression in human breast cancer, a meta-analysis. Onco Targets
Ther. 9:5339–5347. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suárez-Villanueva S, Ayala-Madrigal ML,
Peregrina-Sandoval J, Macías-Gómez N, Ramírez-Ramírez R,
Muñiz-Mendoza R, Moreno-Ortiz JM, Centeno-Flores M,
Maciel-Gutiérrez V, Cabrales E, et al: RUNX3 gene polymorphisms and
haplotypes in Mexican patients with colorectal cancer. Genet Mol
Res. 14:15505–15510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mu WP, Wang J, Niu Q, Shi N and Lian HF:
Clinical significance and association of RUNX3 hypermethylation
frequency with colorectal cancer: A meta-analysis. Onco Targets
Ther. 7:1237–1245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
No authors listed. The Helsinki
Declaration of the World Medical Association (WMA). Ethical
principles of medical research involving human subjects. Pol Merkur
Lekarski. 36:298–301. 2014.In Polish.
|
|
15
|
Wrona A and Jassem J: The new TNM
classification in lung cancer. Pneumonol Alergol Pol. 78:407–417.
2010.In Polish.
|
|
16
|
Ribeiro J, Marinho-Dias J, Monteiro P,
Loureiro J, Baldaque I, Medeiros R and Sousa H: miR-34a and
miR-125b expression in HPV infection and cervical cancer
development. BioMed Res Int. 2015:3045842015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu S, Zheng R, Zhang M, Zhang S, Sun X
and Chen W: Incidence and mortality of colorectal cancer in China,
2011. Chin J Cancer Res. 27:22–28. 2015.PubMed/NCBI
|
|
18
|
Gan L, Chen S, Zhong J, Wang X, Lam EK,
Liu X, Zhang J, Zhou T, Yu J, Si J, et al: ZIC1 is downregulated
through promoter hypermethylation, and functions as a tumor
suppressor gene in colorectal cancer. PLoS One. 6:e169162011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Liu K, Zhang T, Wang Z, Qin X,
Jing X, Wu H, Ji X, He Y and Zhao R: Cortactin promotes colorectal
cancer cell proliferation by activating the EGFR-MAPK pathway.
Oncotarget. 8:1541–1554. 2017.
|
|
20
|
Suliman MA, Zhang Z, Na H, Ribeiro AL,
Zhang Y, Niang B, Hamid AS, Zhang H, Xu L and Zuo Y: Niclosamide
inhibits colon cancer progression through downregulation of the
Notch pathway and upregulation of the tumor suppressor miR-200
family. Int J Mol Med. 38:776–784. 2016.PubMed/NCBI
|
|
21
|
Park J, Kim HJ, Kim KR, Lee SK, Kim H,
Park KK and Chung WY: Loss of RUNX3 expression inhibits bone
invasion of oral squamous cell carcinoma. Oncotarget. 8:9079–9092.
2017.
|
|
22
|
Chen Y, Wang X, Cheng J, Wang Z, Jiang T,
Hou N, Liu N, Song T and Huang C: MicroRNA-20a-5p targets RUNX3 to
regulate proliferation and migration of human hepatocellular cancer
cells. Oncol Rep. 36:3379–3386. 2016.PubMed/NCBI
|
|
23
|
Liu X, Wang L and Guo Y: The association
between runt-related transcription factor 3 gene promoter
methylation and gastric cancer: A meta-analysis. J Cancer Res Ther.
12(Suppl): 50–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li DJ, Shi M and Wang Z: RUNX3 reverses
cisplatin resistance in esophageal squamous cell carcinoma via
suppression of the protein kinase B pathway. Thorac Cancer.
7:570–580. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Yin Y, Hu Y, Feng Y, Bian Z, Yao S,
Li M, You Q and Huang Z: miR-139-5p sensitizes colorectal cancer
cells to 5-fluorouracil by targeting NOTCH-1. Pathol Res Pract.
212:643–649. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Negri FV, Crafa P, Pedrazzi G, Bozzetti C,
Lagrasta C, Gardini G, Tamagnini I, Bisagni A, Azzoni C, Bottarelli
L, et al: Strong Notch activation hinders bevacizumab efficacy in
advanced colorectal cancer. Future Oncol. 11:3167–3174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vinson KE, George DC, Fender AW, Bertrand
FE and Sigounas G: The Notch pathway in colorectal cancer. Int J
Cancer. 138:1835–1842. 2016. View Article : Google Scholar
|
|
28
|
Dai Y, Wilson G, Huang B, Peng M, Teng G,
Zhang D, Zhang R, Ebert MP, Chen J, Wong BC, et al: Silencing of
Jagged 1 inhibits cell growth and invasion in colorectal cancer.
Cell Death Dis. 5:e11702014. View Article : Google Scholar
|
|
29
|
Kodach LL, Jacobs RJ, Heijmans J, van
Noesel CJ, Langers AM, Verspaget HW, Hommes DW, Offerhaus GJ, van
den Brink GR and Hardwick JC: The role of EZH2 and DNA methylation
in the silencing of the tumour suppressor RUNX3 in colorectal
cancer. Carcinogenesis. 31:1567–1575. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang L, Li D, Liu Y, Wang Y, Cui J, Cui A
and Wu W: Expression of RUNX3 and β-catenin in the carcinogenesis
of sporadic colorectal tubular adenoma. Tumour Biol. 35:6039–6046.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kranenburg O: Prometastatic NOTCH
signaling in colon cancer. Cancer Discov. 5:115–117. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ranganathan P, Weaver KL and Capobianco
AJ: Notch signalling in solid tumours: A little bit of everything
but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Subramaniam MM, Chan JY, Soong R, Ito K,
Yeoh KG, Wong R, Guenther T, Will O, Chen CL, Kumarasinghe MP, et
al: RUNX3 inactivation in colorectal polyps arising through
different pathways of colonic carcinogenesis. Am J Gastroenterol.
104:426–436. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang H, Li RP, Liang P, Zhou YL and Wang
GW: miR-125a inhibits the migration and invasion of liver cancer
cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol
Lett. 10:681–686. 2015.PubMed/NCBI
|
|
35
|
Ito K, Lim AC, Salto-Tellez M, Motoda L,
Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, et al: RUNX3
attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
Cancer Cell. 14:226–237. 2008. View Article : Google Scholar : PubMed/NCBI
|
